Genetic Testing Increasingly Guides Prostate Cancer Treatment Decisions
Translated & summarized from NEWSru Israel by baba
Updated guidelines recommend genetic testing for advanced prostate cancer to guide treatment, with studies showing PARP inhibitors benefit patients with specific DNA repair gene mutations like BRCA. While effective, these therapies increase side effect risks, necessitating individualized treatment decisions.
The story in 5 lines · by baba
- Genetic testing is increasingly used to guide advanced prostate cancer treatment.
- PARP inhibitors show significant benefits for patients with DNA repair gene mutations.
- Studies TALAPRO-3 and AMPLITUDE highlight effectiveness in BRCA mutation carriers.
- Combined therapies increase the risk of adverse side effects.
- Treatment decisions must be individualized based on mutations and risks.
Genetic analysis of tumors is becoming a key factor in determining treatment for advanced prostate cancer, according to updated guidelines from the American Urological Association (AUA) and the Society of Urologic Oncology (SUO). These guidelines, published in early October, recommend using somatic and hereditary genetic testing to identify mutations, particularly in DNA repair genes like BRCA1 and BRCA2, which can influence therapeutic choices.
The TALAPRO-3 study, published in the New England Journal of Medicine, demonstrated significant benefits. In the study of 599 patients with metastatic hormone-sensitive prostate cancer and DNA repair gene mutations, adding the PARP inhibitor talazoparib to enzalutamide reduced the risk of disease progression or death by approximately 52%. After three years, 77% of patients on the combination therapy remained progression-free, compared to 56% in the control group, with the most pronounced effect seen in patients with BRCA mutations.
Similar findings emerged from the AMPLITUDE study, published in Nature Medicine, involving 696 patients with DNA repair gene mutations. Adding the PARP inhibitor niraparib to abiraterone and standard hormone therapy lowered the risk of radiological progression or death by 37%, and by 48% specifically in patients with BRCA1/BRCA2 mutations. Again, the benefit was most substantial for BRCA carriers.
However, combined therapies increase the risk of side effects. In TALAPRO-3, severe anemia was more frequent with talazoparib. In AMPLITUDE, 75% of patients receiving niraparib experienced severe adverse events, versus 59% in the control group. Overall survival data from both studies are still pending.
These findings underscore the growing importance of genetic profiling in prostate cancer, as the same clinical stage may require different treatments based on the presence of BRCA and other DNA repair gene mutations. Specialists emphasize that early use of PARP inhibitors is not suitable for all patients, and treatment decisions must consider the specific mutation, disease extent, and risk of complications.
Dr. Avivit Peer, Head of the Genitourinary Tumors Clinic at Rambam Health Care Campus's Oncology Institute, noted in an article by Israeli website Ynet, co-prepared with Johnson & Johnson, that genetic profiling is increasingly part of treatment selection. She highlighted that new research supports earlier use of targeted drugs for some patients with metastatic prostate cancer but stressed that such therapy decisions must be individualized, considering potential side effects.